Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 13;25(20):11013.
doi: 10.3390/ijms252011013.

Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications

Genia Dubrovsky  1   2 , Alison Ross  1 , Pooya Jalali  3 , Michael Lotze  4
Affiliations
Review

Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications

Genia Dubrovsky et al. Int J Mol Sci. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a malignancy with one of the highest mortality rates. One limitation in the diagnosis and treatment of PDAC is the lack of an early and universal biomarker. Extensive research performed recently to develop new assays which could fit this role is available. In this review, we will discuss the current landscape of liquid biopsy in patients with PDAC. Specifically, we will review the various methods of liquid biopsy, focusing on circulating tumor DNA (ctDNA) and exosomes and future opportunities for improvement using artificial intelligence or machine learning to analyze results from a multi-omic approach. We will also consider applications which have been evaluated, including the utility of liquid biopsy for screening and staging patients at diagnosis as well as before and after surgery. We will also examine the potential for liquid biopsy to monitor patient treatment response in the setting of clinical trial development.

Keywords: ctDNA; exosomes; liquid biopsy; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Liquid biopsy flow chart depicting potential analytes and progression of capture and evaluation. Created in BioRender by Ross, A. (2024) (BioRender.com/g43t071, Access date: 10 April 2024).
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. House M.G., Gonen M., Jarnagin W.R., D’Angelica M., DeMatteo R.P., Fong Y., Brennan M.F., Allen P.J. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J. Gastrointest. Surg. 2007;11:1549–1555. doi: 10.1007/s11605-007-0243-7. - DOI - PubMed
    1. Dbouk M., Katona B.W., Brand R.E., Chak A., Syngal S., Farrell J.J., Kastrinos F., Stoffel E.M., Blackford A.L., Rustgi A.K., et al. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J. Clin. Oncol. 2022;40:3257–3266. doi: 10.1200/JCO.22.00298. - DOI - PMC - PubMed
    1. Wood L.D., Canto M.I., Jaffee E.M., Simeone D.M. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology. 2022;163:386–402.e1. doi: 10.1053/j.gastro.2022.03.056. - DOI - PMC - PubMed
    1. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–361. doi: 10.1016/j.cell.2011.11.025. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources